BI
BITRF.US Biotron Limited
- Market cap
- USD 7.80M
- P/E
- -
- P/B
- 3.89x
- ROE
- -52.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is BITRF.US undervalued?
Graham numberThe Graham number of Biotron Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biotron Limited fundamental analysis
No fundamental analysis for Biotron Limited yet.
Biotron Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biotron Limited
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 that is in Phase 2 clinical trial for the treatment of HIV-1, as well as to treat hepatitis C virus infections; and BIT-HBV001 to treat hepatitis B virus and hepatitis delta virus. It also develops preclinical drugs for viral diseases, such as dengue, zika, and influenza virus. Th…
Full company profileBiotron Limited financial statements
Biotron Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.66M | 931.00 | 1.07M | 50.0K | 1.46M | 1.56M | 1.43M | 1.65M | 1.81M | 526K |
| Gross Profit | 1.65M | -10.7K | 1.06M | -119.00 | 1.41M | 1.51M | 1.39M | 1.60M | 1.81M | 526K |
| Operating Income | -4.78M | -3.23M | -2.77M | -3.57M | -3.19M | -2.78M | -3.61M | -3.51M | -339K | -1.56M |
| EBITDA | -3.11M | -1.60M | -1.69M | -3.52M | -3.15M | -2.73M | -3.57M | -3.47M | -327K | -1.55M |
| Net Income | -3.09M | -1.59M | -1.61M | -3.58M | -3.19M | -2.78M | -3.49M | -3.44M | -319K | -1.52M |
| EPS | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 2.06M | 1.62M | 5.86M | 7.83M | 4.33M | 1.91M | 4.14M | 493K | 980K | 3.73M |
| Total Liabilities | 620K | 338K | 418K | 853K | 464K | 814K | 962K | 738K | 429K | 817K |
| Shareholders' Equity | 1.44M | 1.28M | 5.44M | 6.97M | 3.86M | 1.09M | 3.17M | -244K | 552K | 2.92M |
| Cash & Short-term Investments | 1.99M | 1.54M | 5.74M | 7.66M | 4.21M | 1.74M | 3.98M | 393K | 932K | 1.55M |
| Total Debt | - | - | - | 44.0K | 6.35K | 77.2K | 45.3K | 7.13K | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.83M | -1.84M | -1.50M | -3.08M | -3.41M | -2.44M | -3.29M | -3.57M | -566K | -1.77M |
| Capital Expenditure | 5.50K | 40.9K | 40.9K | 5.72K | 5.72K | 0.00 | 0.00 | 0.00 | 3.07K | 4.33 |
| Free Cash Flow | -2.84M | -1.84M | -1.54M | -3.08M | -3.41M | -2.44M | -3.29M | -3.57M | -569K | -1.77M |
| Ratios | ||||||||||
| ROE | -214.8% | -124.4% | -29.6% | -51.3% | -82.7% | -254.6% | -110.1% | - | -57.7% | -52.0% |
| ROA | -150.2% | -98.4% | -27.5% | -45.7% | -73.8% | -145.9% | -84.5% | -696.4% | -32.5% | -40.6% |
| Net Profit Margin | -186.4% | -171,175.6% | -150.2% | -7,151.9% | -218.5% | -178.4% | -244.0% | -208.9% | -17.6% | -288.3% |
| Debt to Equity | - | - | - | 0.01x | 0.00x | 0.07x | 0.01x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Biotron Limited dividends
Biotron Limited has not paid dividends in the last 10 fiscal years.
Last stock split: 129:125 on Nov 8, 2022.
Who owns Biotron Limited
- Insiders 37.57%
- Institutions 0.00%
- Public & others 62.43%
- Shares outstanding 2.79B
- Free float 1.96B
Biotron Limited company profile
- Company name
- Biotron Limited
- Ticker
- BITRF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 66 Hunter Street, Sydney, NSW, Australia, 2000
- Phone
- 61 2 9300 3344
- Website
- biotron.com.au
About Biotron Limited
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 that is in Phase 2 clinical trial for the treatment of HIV-1, as well as to treat hepatitis C virus infections; and BIT-HBV001 to treat hepatitis B virus and hepatitis delta virus. It also develops preclinical drugs for viral diseases, such as dengue, zika, and influenza virus. The company was incorporated in 1999 and is based in Sydney, Australia.
Biotron Limited management
1- Mr. Marcelo Mora ACIS, B.Bus AasaCompany Secretary